Modified Therapeutic Antibodies: Improving Efficacy
The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodies for the treatment of cancers, inflammatory disorders, and refractory infections. As drawbacks emerge in clinical trials and practice, such as impeded binding, reduced effector functions,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Engineering |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095809921003040 |
| _version_ | 1818366229281243136 |
|---|---|
| author | Ji-Min Dai Xue-Qin Zhang Jing-Yao Dai Xiang-Min Yang Zhi-Nan Chen |
| author_facet | Ji-Min Dai Xue-Qin Zhang Jing-Yao Dai Xiang-Min Yang Zhi-Nan Chen |
| author_sort | Ji-Min Dai |
| collection | DOAJ |
| description | The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodies for the treatment of cancers, inflammatory disorders, and refractory infections. As drawbacks emerge in clinical trials and practice, such as impeded binding, reduced effector functions, and frequent adverse reactions, modifications of therapeutic antibodies are unprecedently burgeoning in research and development (R&D). These modifications include: ① modified glycosylation; ② fragment of crystallizable domain (Fc) amino acid alterations; ③ cross-isotype or cross-subclass exchanges; ④ antibody–drug conjugates (ADCs); ⑤ single chain of variable region fragment (scFv) for chimeric antigen receptor T (CAR-T) cells; and ⑥ bispecific antibodies (bsAbs) in order to promote binding affinity, half-life in circulation, effectiveness toward target cells and, ultimately, to achieve overall improved efficacy. While many achievements have been made around the world in the past decades, China has been playing an active role in this realm, with its great demand for biotherapeutics with R&D potential. This review recapitulates the international progress that has been achieved with modified therapeutic antibodies, and then focuses on that of China in an independent section. |
| first_indexed | 2024-12-13T22:32:50Z |
| format | Article |
| id | doaj.art-27b2809fef0147f080daf8c855001e5d |
| institution | Directory Open Access Journal |
| issn | 2095-8099 |
| language | English |
| last_indexed | 2024-12-13T22:32:50Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Engineering |
| spelling | doaj.art-27b2809fef0147f080daf8c855001e5d2022-12-21T23:29:02ZengElsevierEngineering2095-80992021-11-0171115291540Modified Therapeutic Antibodies: Improving EfficacyJi-Min Dai0Xue-Qin Zhang1Jing-Yao Dai2Xiang-Min Yang3Zhi-Nan Chen4Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China; Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, ChinaDepartment of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China; Department of Hepatobiliary Surgery, Air Force Medical Center, Beijing 100142, ChinaDepartment of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China; Corresponding authors.Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China; Corresponding authors.The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodies for the treatment of cancers, inflammatory disorders, and refractory infections. As drawbacks emerge in clinical trials and practice, such as impeded binding, reduced effector functions, and frequent adverse reactions, modifications of therapeutic antibodies are unprecedently burgeoning in research and development (R&D). These modifications include: ① modified glycosylation; ② fragment of crystallizable domain (Fc) amino acid alterations; ③ cross-isotype or cross-subclass exchanges; ④ antibody–drug conjugates (ADCs); ⑤ single chain of variable region fragment (scFv) for chimeric antigen receptor T (CAR-T) cells; and ⑥ bispecific antibodies (bsAbs) in order to promote binding affinity, half-life in circulation, effectiveness toward target cells and, ultimately, to achieve overall improved efficacy. While many achievements have been made around the world in the past decades, China has been playing an active role in this realm, with its great demand for biotherapeutics with R&D potential. This review recapitulates the international progress that has been achieved with modified therapeutic antibodies, and then focuses on that of China in an independent section.http://www.sciencedirect.com/science/article/pii/S2095809921003040Therapeutic antibodyModificationEfficacyAntigenAntibody–drug conjugateBispecific antibody |
| spellingShingle | Ji-Min Dai Xue-Qin Zhang Jing-Yao Dai Xiang-Min Yang Zhi-Nan Chen Modified Therapeutic Antibodies: Improving Efficacy Engineering Therapeutic antibody Modification Efficacy Antigen Antibody–drug conjugate Bispecific antibody |
| title | Modified Therapeutic Antibodies: Improving Efficacy |
| title_full | Modified Therapeutic Antibodies: Improving Efficacy |
| title_fullStr | Modified Therapeutic Antibodies: Improving Efficacy |
| title_full_unstemmed | Modified Therapeutic Antibodies: Improving Efficacy |
| title_short | Modified Therapeutic Antibodies: Improving Efficacy |
| title_sort | modified therapeutic antibodies improving efficacy |
| topic | Therapeutic antibody Modification Efficacy Antigen Antibody–drug conjugate Bispecific antibody |
| url | http://www.sciencedirect.com/science/article/pii/S2095809921003040 |
| work_keys_str_mv | AT jimindai modifiedtherapeuticantibodiesimprovingefficacy AT xueqinzhang modifiedtherapeuticantibodiesimprovingefficacy AT jingyaodai modifiedtherapeuticantibodiesimprovingefficacy AT xiangminyang modifiedtherapeuticantibodiesimprovingefficacy AT zhinanchen modifiedtherapeuticantibodiesimprovingefficacy |